Sweden’s Xbrane Biopharma is moving to new premises that will expand its development capacity and allow it to target several blockbuster biologics with patents expiring over the next decade.
Sweden’s Xbrane Biopharma has announced a move to new premises that will expand its biosimilar development capacity and allow it to target a number of new biologic brands, allowing it to “take the next step in the company’s ambition to become a leading global biosimilar developer and broaden its biosimilar portfolio.”
The move, to a campus in Solna near Stockholm, will see Xbrane set up a new development lab for biosimilars...
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
